Rhumbline Advisers Purchases 25,292 Shares of Insmed Incorporated (NASDAQ:INSM)

Rhumbline Advisers raised its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 9.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 288,337 shares of the biopharmaceutical company's stock after purchasing an additional 25,292 shares during the period. Rhumbline Advisers owned approximately 0.16% of Insmed worth $19,907,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in INSM. V Square Quantitative Management LLC increased its stake in Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 248 shares during the period. Values First Advisors Inc. raised its stake in shares of Insmed by 4.4% in the fourth quarter. Values First Advisors Inc. now owns 5,199 shares of the biopharmaceutical company's stock valued at $359,000 after purchasing an additional 221 shares in the last quarter. Legato Capital Management LLC raised its stake in shares of Insmed by 2.2% in the fourth quarter. Legato Capital Management LLC now owns 36,871 shares of the biopharmaceutical company's stock valued at $2,546,000 after purchasing an additional 792 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Insmed by 8.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 423,094 shares of the biopharmaceutical company's stock worth $29,590,000 after buying an additional 32,960 shares in the last quarter. Finally, Financial Advocates Investment Management bought a new stake in Insmed in the 4th quarter valued at $335,000.

Analyst Ratings Changes

Several research firms recently commented on INSM. Wells Fargo & Company raised their target price on Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a research report on Wednesday. Cantor Fitzgerald reiterated an "overweight" rating on shares of Insmed in a research note on Wednesday. Guggenheim boosted their target price on shares of Insmed from $95.00 to $101.00 and gave the company a "buy" rating in a research note on Friday, February 7th. JPMorgan Chase & Co. increased their target price on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research report on Friday, February 7th. Finally, HC Wainwright reissued a "buy" rating and set a $90.00 price target on shares of Insmed in a report on Friday. One research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $91.00.

Insmed Trading Down 3.0 %

NASDAQ INSM traded down $2.55 during trading on Friday, reaching $81.06. 2,722,240 shares of the stock traded hands, compared to its average volume of 1,948,698. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a market cap of $14.50 billion, a price-to-earnings ratio of -14.61 and a beta of 1.11. The stock's 50-day moving average price is $74.29 and its 200 day moving average price is $73.59.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Analysts predict that Insmed Incorporated will post -5.42 EPS for the current year.

Insider Buying and Selling at Insmed

In other Insmed news, CFO Sara Bonstein sold 18,322 shares of Insmed stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total value of $1,471,439.82. Following the transaction, the chief financial officer now owns 118,863 shares of the company's stock, valued at approximately $9,545,887.53. The trade was a 13.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO William Lewis sold 18,750 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the sale, the chief executive officer now directly owns 334,186 shares of the company's stock, valued at $27,079,091.58. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 532,207 shares of company stock valued at $41,400,465. Company insiders own 4.60% of the company's stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.